Dublin, Dec. 17, 2020 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global cystic fibrosis therapeutics market grew at a CAGR of around 15% during 2014-2019. Cystic fibrosis (CF) is a rare and progressive genetic disorder that is characterized by an abnormal movement of sodium and chloride across the gastrointestinal and respiratory tracts. This disorder can cause the development of viscous secretions in the lungs, pancreas, intestines and liver. The management and treatment of CF involve physical therapy, gene therapy, physiotherapy and nutritional support. Along with this, gene therapy and medicinal drugs, such as pancreatic enzyme supplements, mucolytics, bronchodilators and cystic fibrosis transmembrane conductance regulator (CFTR) modulators are also used for targeting cellular interactomes and symptomatic improvement. These drugs can be administered to the patient orally or by inhalation.

The rising incidence of cystic fibrosis across the globe, along with improvements in the diagnostic technologies of the disorder, is one of the key factors driving the growth of the market. Furthermore, widespread adoption of cystic fibrosis transmembrane conductance (CFTR) modulators as a treatment alternative is also providing a boost to the market growth. CFTRs are configured to regulate the flow of water and chloride through cell linings of the lungs and other organs and correct the malfunctioning protein in the body.

Additionally, various technological advancements, such as the development of personalized drug therapy, molecular prosthetics and innovative drugs with improved efficacy, are acting as another growth-inducing factor. Other factors, including rising healthcare expenditures, increasing health consciousness, and awareness regarding the available treatment options for cystic fibrosis, are projected to drive the market further. Looking forward, the publisher expects the market to continue to exhibit strong growth during 2020-2025.

Breakup by Drug Class:

Breakup by Drug Molecule Type:

Breakup by Route of Administration:

Breakup by End-User:

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alaxia, Alcresta Therapeutics Inc., Allergan, AstraZeneca, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., etc.

Key Questions Answered in this Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction 4.1 Overview 4.2 Key Industry Trends

5 Global Cystic Fibrosis Therapeutics Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Forecast

6 Market Breakup by Drug Class 6.1 Pancreatic Enzyme Supplements 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Mucolytics 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Bronchodilators 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 CFTR Modulators 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Antibiotics 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Others 6.6.1 Market Trends 6.6.2 Market Forecast

7 Market Breakup by Drug Molecule Type 7.1 Small Molecule Drugs 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Biologics 7.2.1 Market Trends 7.2.2 Market Forecast

8 Market Breakup by Route of Administration 8.1 Oral Drugs 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Inhaled Drugs 8.2.1 Market Trends 8.2.2 Market Forecast

9 Market Breakup by End-User 9.1 Hospitals 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Clinics 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Others 9.3.1 Market Trends 9.3.2 Market Forecast

10 Market Breakup by Region 10.1 North America 10.1.1 United States 10.1.1.1 Market Trends 10.1.1.2 Market Forecast 10.1.2 Canada 10.1.2.1 Market Trends 10.1.2.2 Market Forecast 10.2 Asia Pacific 10.2.1 China 10.2.1.1 Market Trends 10.2.1.2 Market Forecast 10.2.2 Japan 10.2.2.1 Market Trends 10.2.2.2 Market Forecast 10.2.3 India 10.2.3.1 Market Trends 10.2.3.2 Market Forecast 10.2.4 South Korea 10.2.4.1 Market Trends 10.2.4.2 Market Forecast 10.2.5 Australia 10.2.5.1 Market Trends 10.2.5.2 Market Forecast 10.2.6 Indonesia 10.2.6.1 Market Trends 10.2.6.2 Market Forecast 10.2.7 Others 10.2.7.1 Market Trends 10.2.7.2 Market Forecast 10.3 Europe 10.3.1 Germany 10.3.1.1 Market Trends 10.3.1.2 Market Forecast 10.3.2 France 10.3.2.1 Market Trends 10.3.2.2 Market Forecast 10.3.3 United Kingdom 10.3.3.1 Market Trends 10.3.3.2 Market Forecast 10.3.4 Italy 10.3.4.1 Market Trends 10.3.4.2 Market Forecast 10.3.5 Spain 10.3.5.1 Market Trends 10.3.5.2 Market Forecast 10.3.6 Russia 10.3.6.1 Market Trends 10.3.6.2 Market Forecast 10.3.7 Others 10.3.7.1 Market Trends 10.3.7.2 Market Forecast 10.4 Latin America 10.4.1 Brazil 10.4.1.1 Market Trends 10.4.1.2 Market Forecast 10.4.2 Mexico 10.4.2.1 Market Trends 10.4.2.2 Market Forecast 10.4.3 Others 10.4.3.1 Market Trends 10.4.3.2 Market Forecast 10.5 Middle East and Africa 10.5.1 Market Trends 10.5.2 Market Breakup by Country 10.5.3 Market Forecast

11 SWOT Analysis 11.1 Overview 11.2 Strengths 11.3 Weaknesses 11.4 Opportunities 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis 13.1 Overview 13.2 Bargaining Power of Buyers 13.3 Bargaining Power of Suppliers 13.4 Degree of Competition 13.5 Threat of New Entrants 13.6 Threat of Substitutes

14 Price Indicators

15 Competitive Landscape 15.1 Market Structure 15.2 Key Players 15.3 Profiles of Key Players 15.3.1 Abbvie Inc. 15.3.1.1 Company Overview 15.3.1.2 Product Portfolio 15.3.1.3 Financials 15.3.1.4 SWOT Analysis 15.3.2 Alaxia 15.3.2.1 Company Overview 15.3.2.2 Product Portfolio 15.3.3 Alcresta Therapeutics Inc. 15.3.3.1 Company Overview 15.3.3.2 Product Portfolio 15.3.4 Allergan 15.3.4.1 Company Overview 15.3.4.2 Product Portfolio 15.3.4.3 Financials 15.3.4.4 SWOT Analysis 15.3.5 AstraZeneca 15.3.5.1 Company Overview 15.3.5.2 Product Portfolio 15.3.5.3 Financials 15.3.5.4 SWOT Analysis 15.3.6 F. Hoffmann-La Roche Ltd 15.3.6.1 Company Overview 15.3.6.2 Product Portfolio 15.3.7 Gilead Sciences Inc. 15.3.7.1 Company Overview 15.3.7.2 Product Portfolio 15.3.7.3 Financials 15.3.7.4 SWOT Analysis 15.3.8 Merck & Co., Inc. 15.3.8.1 Company Overview 15.3.8.2 Product Portfolio 15.3.8.3 Financials 15.3.8.4 SWOT Analysis 15.3.9 Novartis AG 15.3.9.1 Company Overview 15.3.9.2 Product Portfolio 15.3.9.3 Financials 15.3.9.4 SWOT Analysis 15.3.10 Teva Pharmaceutical Industries Ltd. 15.3.10.1 Company Overview 15.3.10.2 Product Portfolio 15.3.10.3 Financials 15.3.10.4 SWOT Analysis 15.3.11 Vertex Pharmaceuticals Inc. 15.3.11.1 Company Overview 15.3.11.2 Product Portfolio 15.3.11.3 Financials 15.3.11.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/jx25ft

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See original here:
Worldwide Industry for Cystic Fibrosis Therapeutics to 2025 - Players Include AbbVie, Alaxia and Alcresta Therapeutics Among Others - Stockhouse